Literature DB >> 23275602

Graft-versus-host disease impairs vaccine responses through decreased CD4+ and CD8+ T cell proliferation and increased perforin-mediated CD8+ T cell apoptosis.

Christian M Capitini1, Nicole M Nasholm, Brynn B Duncan, Martin Guimond, Terry J Fry.   

Abstract

Tumor-targeted vaccines represent a strategy to enhance the graft-versus-leukemia effect after allogeneic blood and marrow transplantation (BMT). We have previously shown that graft-versus-host disease (GVHD) can negatively impact quantitative responses to vaccines. Using a minor histocompatibility Ag-mismatched BMT (B6 → B6 × C3H.SW) followed by adoptive transfer of HY-specific T cells and HY-expressing dendritic cells, we assessed whether GVHD induced by donor lymphocyte infusion (DLI) affects the persistence, proliferation, and survival of vaccine-responding, nonalloantigen reactive T cells. Both CD8(+) and CD4(+) HY-specific T cells undergo less vaccine-driven proliferation in allogeneic recipients with GVHD. Although vaccine-responding CD8(+) T cells show decreased IFN-γ and CD107a production, CD4(+) T cells exhibit increased programmed death 1 and T cell Ig mucin-like domain 3 expression. In addition, the degree of apoptosis in vaccine-responding CD8(+) T cells was higher in the presence of GVHD, but there was no difference in CD4(+) T cell apoptosis. Using Fas ligand-deficient or TRAIL-deficient DLI had no impact on apoptosis of HY-specific T cells. However, perforin-deficient alloreactive DLI induced significantly less apoptosis of vaccine-responding CD8(+) T cells and resulted in enhanced tumor protection. Thus, diminished vaccine responses during GVHD result from impaired proliferation of CD8(+) and CD4(+) T cells responding to vaccination, with an additional contribution from perforin-mediated CD8(+) T cell apoptosis. These results provide important insights toward optimizing vaccine responses after allogeneic BMT.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23275602      PMCID: PMC3626171          DOI: 10.4049/jimmunol.1200391

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  44 in total

1.  Cross-primed CD8(+) T cells mediate graft rejection via a distinct effector pathway.

Authors:  Anna Valujskikh; Olivier Lantz; Susanna Celli; Polly Matzinger; Peter S Heeger
Journal:  Nat Immunol       Date:  2002-08-12       Impact factor: 25.606

2.  Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation.

Authors:  T A Graubert; J F DiPersio; J H Russell; T J Ley
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

3.  Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool.

Authors:  Fraia Melchionda; Terry J Fry; Matthew J Milliron; Melissa A McKirdy; Yutaka Tagaya; Crystal L Mackall
Journal:  J Clin Invest       Date:  2005-04-07       Impact factor: 14.808

4.  Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect.

Authors:  C Schmaltz; O Alpdogan; K J Horndasch; S J Muriglan; B J Kappel; T Teshima; J L Ferrara; S J Burakoff; M R van den Brink
Journal:  Blood       Date:  2001-05-01       Impact factor: 22.113

5.  Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease.

Authors:  L D Anderson; S Mori; S Mann; C A Savary; C A Mullen
Journal:  Cancer Res       Date:  2000-10-15       Impact factor: 12.701

6.  Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation.

Authors:  T Teshima; N Mach; G R Hill; L Pan; S Gillessen; G Dranoff; J L Ferrara
Journal:  Cancer Res       Date:  2001-01-01       Impact factor: 12.701

7.  Increased apoptosis of peripheral blood T cells following allogeneic hematopoietic cell transplantation.

Authors:  M T Lin; L H Tseng; H Frangoul; T Gooley; J Pei; A Barsoukov; Y Akatsuka; J A Hansen
Journal:  Blood       Date:  2000-06-15       Impact factor: 22.113

8.  Functional unresponsiveness and replicative senescence of myeloid leukemia antigen-specific CD8+ T cells after allogeneic stem cell transplantation.

Authors:  Gregory L Beatty; Jasmine S Smith; Ran Reshef; Kunal P Patel; Theresa A Colligon; Barbara A Vance; Noelle V Frey; F Brad Johnson; David L Porter; Robert H Vonderheide
Journal:  Clin Cancer Res       Date:  2009-07-14       Impact factor: 12.531

9.  Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production.

Authors:  A Shustov; P Nguyen; F Finkelman; K B Elkon; C S Via
Journal:  J Immunol       Date:  1998-09-15       Impact factor: 5.422

10.  The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice.

Authors:  M B Baker; N H Altman; E R Podack; R B Levy
Journal:  J Exp Med       Date:  1996-06-01       Impact factor: 14.307

View more
  6 in total

Review 1.  Challenges and opportunities of allogeneic donor-derived CAR T cells.

Authors:  Yinmeng Yang; Elad Jacoby; Terry J Fry
Journal:  Curr Opin Hematol       Date:  2015-11       Impact factor: 3.284

2.  Minor antigen distribution predicts site-specific graft-versus-tumor activity of adoptively transferred, minor antigen-specific CD8 T Cells.

Authors:  Jessica C Shand; Haiying Qin; Nicole Nasholm; Christian M Capitini; Terry J Fry
Journal:  Biol Blood Marrow Transplant       Date:  2013-10-17       Impact factor: 5.742

3.  Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD.

Authors:  Elad Jacoby; Yinmeng Yang; Haiying Qin; Christopher D Chien; James N Kochenderfer; Terry J Fry
Journal:  Blood       Date:  2015-12-11       Impact factor: 22.113

Review 4.  Cytotoxic Pathways in Allogeneic Hematopoietic Cell Transplantation.

Authors:  Wei Du; Xuefang Cao
Journal:  Front Immunol       Date:  2018-12-19       Impact factor: 7.561

5.  Tumor-targeting vaccination instructs graft-vs.-tumor immune responses.

Authors:  Teresa Manzo; Rodrigo Hess Michelini; Tabea Sturmheit; Veronica Basso; Matteo Bellone; Anna Mondino
Journal:  Oncoimmunology       Date:  2013-09-12       Impact factor: 8.110

6.  Severe COVID-19 in a patient with chronic graft-versus-host disease after hematopoietic stem cell transplant successfully treated with ruxolitinib.

Authors:  Francesco Saraceni; Ilaria Scortechini; Giorgia Mancini; Marianna Mariani; Irene Federici; Mariana Gaetani; Paolo Barbatelli; Maria Luisa Minnucci; Patrizia Bagnarelli; Attilio Olivieri
Journal:  Transpl Infect Dis       Date:  2020-07-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.